#Lilly #Orfoglipron #OralTherapies #PharmaManufacturing #GlobalSupply #Obesity #Diabetes #PatientAccess #SupplyChainResilience Lilly Expands Manufacturing Footprint with $3B European Facility Lilly announced plans to build a $3B (2.6B) state-of-the-art facility in Katwijk, Netherlands (Leiden Bio Science Park) to boost oral medicine manufacturing capacity and meet growing global demand across cardiometabolic, neuroscience, oncology, and immunology therapies
A limited number of small human studies suggest possible benefits for skin firmness and wound healing, but these trials were often short-term and lacked rigorous control groups
But that delicate structure, so carefully preserved, is also incredibly vulnerable when its time to wake it up
Discrepancies between these studies suggest that the N
These drugs may raise levels of insulin-like growth factor 1 (IGF-1)
These initial experiences do not predict long-term outcomes